Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 321 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
321 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial evaluates a personalized multi-peptide neo-antigen vaccine combined with poly ICLC and the PD-1 inhibitor nivolumab in adult patients with advanced, treatment-resistant stage IIIC-IV melanoma, hormone receptor positive HER2-negative metastatic breast cancer, and stage III-IV non-small cell lung cancer, focusing on safety and immune response.
ClinicalTrials.gov ID: NCT05098210
TrialFetch AI summary: This trial investigates LNCB74, a B7-H4 targeted antibody-drug conjugate, as monotherapy for adults with advanced, unresectable, or metastatic solid tumors that express B7-H4, aiming to evaluate its safety, tolerability, and efficacy. Participants must have measurable disease, an ECOG performance status of 0-1, and adequate organ function.
ClinicalTrials.gov ID: NCT06774963
TrialFetch AI summary: This trial evaluates IAM1363, an oral, irreversible tyrosine kinase inhibitor targeting HER2 mutations, in adult patients with advanced cancers harboring HER2 alterations who have relapsed or are intolerant to previous therapies, including a subgroup with brain metastases.
ClinicalTrials.gov ID: NCT06253871
TrialFetch AI summary: This trial enrolls adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express EGFR and have lost HLA-A*02 expression, including types such as CRC, NSCLC, HNSCC, TNBC, and RCC, and tests A2B395, a logic-gated Tmod™ CAR T-cell therapy designed to selectively target these tumor cells while sparing healthy cells. Participants receive a preconditioning lymphodepletion regimen followed by a single intravenous dose of A2B395.
ClinicalTrials.gov ID: NCT06682793
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors, especially those with DNA damage repair deficiencies or PTGR1 overexpression, who have progressed after standard therapies. Patients receive LP-184, a PTGR1-activated prodrug that induces DNA double-strand breaks, as monotherapy or in combination with spironolactone (for recurrent glioblastoma) or olaparib (for triple negative breast cancer).
ClinicalTrials.gov ID: NCT05933265
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors—including HER2-positive or hormone receptor-positive/HER2-negative breast cancer, KRAS-mutant colorectal cancer, or KRAS-mutant non-small cell lung cancer—who have received prior standard therapies, to receive BBO-10203 (a first-in-class PI3Kα:RAS interaction breaker that disrupts PI3Kα-AKT signaling) as monotherapy or in combination with trastuzumab. Key exclusions include untreated brain metastases and extensive prior ADC exposure in HER2+ breast cancer.
ClinicalTrials.gov ID: NCT06625775
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic solid tumors—including urothelial, triple negative breast, non-small cell lung, esophageal, pancreatic, ovarian, cervical (squamous), head and neck squamous cell, and prostate cancers—who have exhausted standard therapies and have ECOG 0–1. All participants receive intravenous LY4101174, a novel antibody-drug conjugate targeting nectin-4 and delivering a topoisomerase I inhibitor (exatecan).
ClinicalTrials.gov ID: NCT06238479
TrialFetch AI summary: Adults with advanced solid tumors and good performance status are eligible for this study of BMS-986507, a bispecific EGFR/HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, in combination with either osimertinib or pembrolizumab. Key exclusions include untreated symptomatic CNS metastases, mixed SCLC/NSCLC, and severe infection or cardiac disease.
ClinicalTrials.gov ID: NCT06618287
TrialFetch AI summary: This trial enrolls adults with metastatic HR+/HER2- breast cancer and other advanced solid tumors likely dependent on CDK4 activity, who have progressed on or are intolerant to standard therapies, to receive the investigational CDK4 inhibitor BGB-43395 (a selective CDK4 inhibitor with minimal CDK6 inhibition) as monotherapy or combined with fulvestrant or letrozole. Prior CDK4/6 inhibitor exposure is permitted and sometimes required, but prior selective CDK4 inhibitors are excluded.
ClinicalTrials.gov ID: NCT06120283
TrialFetch AI summary: This trial enrolls adults with advanced, recurrent, or metastatic solid tumors (including platinum-resistant ovarian cancer, triple-negative breast cancer, squamous cell carcinoma of the anus or head and neck, non-small cell lung cancer, and uterine serous cancer) who have progressed on all standard therapies, to receive SMP-3124LP, a novel liposomal CHK1 inhibitor given by intravenous infusion. SMP-3124LP targets the DNA damage response pathway and is being assessed for safety, tolerability, and preliminary efficacy.
ClinicalTrials.gov ID: NCT06526819